Role of Human Placental Efflux Transporter P-Glycoprotein in the Transfer of Buprenorphine, Levo-α-Acetylmethadol, and Paclitaxel

ABSTRACT

This study examines the role of placental P-glycoprotein (P-gp) in the transfer of buprenorphine (BUP) and l-α-acetylmethadol (LAAM) across the dually perfused human placental lobule. BUP (10 ng/mL) and LAAM (35 ng/mL) were perfused in the maternal-to-fetal direction. The following kinetic parameters were determined: fetal transfer rate (TR_f), maternal clearance (Cl_m), and clearance index (Cl_index). The opiates were perfused in the presence of P-gp inhibitor GF120918 (experimental group) and in its absence (control group). The kinetic parameters for the control group were set at 100% and were as follows for LAAM in the experimental group: TR_f, 123 ± 20%, Cl_m 116 ± 23%, and Cl_index 123 ± 22% (P < 0.05). The corresponding parameters for BUP were not different from controls. The data indicate that LAAM, but not BUP, is extruded by the efflux transporter P-gp. Therefore, it is reasonable to assume that the activity of P-gp could be one of the factors affecting the extent of fetal exposure to LAAM during pregnancy.

KEYWORDS

Buprenorphine - levo-α-acetylmethadol - P-glycoprotein - human placenta

REFERENCES

• 1 Rosen T S, Pippenger C E. Disposition of methadone and its relationship to severity of withdrawal in the newborn. Addictive diseases.  Int J. 1975;  2 169-178
• 2 Kandall S R, Albin S, Gartner L M, Lee K, Eidelman A, Lowinson J. The narcotic-dependent mother: fetal and neonatal consequences.  Early Hum Dev. 1977;  1 159-169
• 3 Brown H L, Britton K A, Mahaffey D, Brizendine E, Hiett A K, Turnquest M A. Methadone maintenance in pregnancy: a reappraisal.  Am J Obstet Gynecol. 1998;  179 459-463
• 4 Fischer G, Johnson R E, Eder H et al.. Treatment of opioid-dependent pregnant women with buprenorphine.  Addiction. 2000;  95 239-244
• 5 Jones H E, Johnson R E, Jasinski D R et al.. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome.  Drug Alcohol Depend. 2005;  79 1-10
• 6 Johnson R E, Chutuape M A, Strain E C, Walsh S L, Stitzer M L, Bigelow G E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.  N Engl J Med. 2000;  343 1290-1297
• 7 Walsh S L, Johnson R E, Cone E J, Bigelow G E. Intravenous and oral l-alpha-acetylmethadol: pharmacodynamics and pharmacokinetics in humans.  J Pharmacol Exp Ther. 1998;  285 71-82
• 8 Nanovskaya T, Deshmukh S, Brooks M, Ahmed M. Transplacental transfer and metabolism of buprenorphine.  J Pharmacol Exp Ther. 2002;  300 26-33
• 9 Nanovskaya T N, Deshmukh S V, Miles R, Burmaster S, Ahmed M S. Transfer of L-alpha-acetylmethadol (LAAM) and L-alpha-acetyl-N-normethadol (norLAAM) by the perfused human placental lobule.  J Pharmacol Exp Ther. 2003;  306 205-212
• 10 Nekhayeva I A, Nanovskaya T N, Deshmukh S V, Zharikova O L, Hankins G D, Ahmed M S. Bidirectional transfer of methadone across human placenta.  Biochem Pharmacol. 2005;  69 187-197
• 11 Johnson R E, Jones H E, Fischer G. Use of buprenorphine in pregnancy: patient management and effects on the neonate.  Drug Alcohol Depend. 2003;  70 S87-S101
• 12 Young A M, Allen C E, Audus K L. Efflux transporters of the human placenta.  Adv Drug Deliv Rev. 2003;  55 125-132
• 13 Nakamura Y, Ikeda S, Furukawa T et al.. Function of P-glycoprotein expressed in placenta and mole.  Biochem Biophys Res Commun. 1997;  235 849-853
• 14 Ushigome F, Takanaga H, Matsuo H et al.. Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein.  Eur J Pharmacol. 2000;  408 1-10
• 15 Schinkel A H, Jonker J W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview.  Adv Drug Deliv Rev. 2003;  55 3-29
• 16 Nanovskaya T, Nekhayeva I, Karunaratne N, Audus K, Hankins G D, Ahmed M S. Role of P-glycoprotein in transplacental transfer of methadone.  Biochem Pharmacol. 2005;  69 1869-1878
• 17 Miller R K, Wier P J, Maulik D, Di Sant'Agnese P A. Human placenta in vitro: Characterization during 12 h of dual perfusion.  Contrib Gynecol Obstet. 1985;  13 77-84
• 18 Traunecker H C, Stevens M C, Kerr D J, Ferry D R. The acridonecarboxamide GF120918 potently reverses P-glycoprotein-mediated resistance in human sarcoma MES-Dx5 cells.  Br J Cancer. 1999;  81 942-951
• 19 Yusuf R Z, Duan Z, Lamendola D E, Penson R T, Seiden M V. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.  Curr Cancer Drug Targets. 2003;  3 1-19
• 20 Litman T, Druley T E, Stein W D, Bates S E. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance.  Cell Mol Life Sci. 2001;  58 931-959
• 21 Martin C, Berridge G, Higgins C F, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binding sites on P-glycoprotein.  Mol Pharmacol. 2000;  58 624-632
• 22 Ueda K, Okamura N, Hirai M et al.. Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone.  J Biol Chem. 1992;  267 24248-24252
• 23 Shapiro A B, Fox K, Lam P, Ling V. Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.  Eur J Biochem. 1999;  259 841-850
• 24 Schneider H. Techniques: in vitro perfusion of human placenta. In: Sastry BV Placental Toxicology. Boca Raton, FL; CRC Press 1995: 1-26
• 25 Hoffmeyer S, Burk O, von Richter O et al.. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.  Proc Natl Acad Sci USA. 2000;  97 3473-3478
• 26 Tanabe M, Ieiri I, Nagata N et al.. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene.  J Pharmacol Exp Ther. 2001;  297 1137-1143
• 27 de Bruin N M, Ellenbroek B A, Cools A R, Coenen A M, van Luijtelaar E L. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats.  Psychopharmacology (Berl). 1999;  142 9-17